Navigation Links
PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
Date:2/18/2009

PRINCETON, N.J., Feb. 18 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company") (Nasdaq: PDGI), a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced the opening of a new office in Sao Paulo, Brazil to further enhance its Latin American presence.

PharmaNet has been providing clinical trial support in Latin America since 2002 with a network of field-based staff in Brazil, Mexico and Peru and an office in Argentina which opened in 2003. The new office in Sao Paulo, Brazil underscores the Company's commitment to serve the needs of its clients in this region. Brazil is a highly desired location for clinical research due to its qualified investigators, large patient population, high standard of care and rigorous regulatory standards which are aligned with US and EU regulations.

"The number of clinical trials in Latin America has experienced significant growth over the past ten years," said Fernanda Duran, executive director, Latin American operations. "Our clients are more actively requesting Latin American sites in order to meet aggressive timelines for patient recruitment, thus bringing their new drugs to market sooner. I am thrilled about opening this office in Brazil which will enhance our infrastructure in the region."

"We are excited to continue our expansion into Latin America, a region which offers excellent resources for conducting clinical trials," said Jeffrey P. McMullen, president and chief executive officer. "In addition to our Buenos Aires office, we have superior field-based staff in the area and the new office will provide them with the facilities to continue to demonstrate their high-quality work for our clients."

PharmaNet's increased presence and capacity in th
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmaNet Development Group Agrees to be Acquired by JLL Partners
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... and RARITAN, N.J. , ... LLC (Janssen) announced data from the Phase 3 ... in progression-free survival (PFS) with trabectedin (YONDELIS ® ... liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with ... regimen. SAR3007 is the largest randomized Phase 3 ...
(Date:6/1/2015)... NEW YORK , June 1, 2015 ... produced by the fermentation of sugar or cellulose. Bio-alcohols ... bio-ethanol can be used as a replacement for gasoline ... to grow at a CAGR of 9 percent over ... Report The global bio-alcohols market can be segmented into ...
(Date:6/1/2015)... EAST HANOVER, N.J. , June 1, 2015 ... Phase II clinical study of CTL019, an investigational ... indicate its potential in the treatment of specific ... ongoing study conducted by the University of Pennsylvania,s ... relapsed or refractory (r/r) diffuse large B-cell lymphoma ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it will present at the Biotech Showcase ... Francisco. (Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ...
... Jan. 4, 2011 Vaccinex, Inc. announced today that ... a Phase 1 clinical trial to assess the safety, ... in cancer patients with advanced solid tumors. ... novel humanized antibody that blocks the activity of semaphorin ...
... S.C., Jan. 4, 2011 Zeus, Inc., a global ... it has expanded its capabilities and is now able ... new 5,000-sq-ft Class 7 manufacturing environment. This expansion allows ... more controlled environment, resulting in compliance with stricter regulatory ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... of fossil speculation across the American West escalated into a ... the spectacle were two scientists from the Lone Star State: ... Texas Geology, and naturalist Jacob Boll, who made many of ... supporting roles in the Bone Wars through their work for ...
... University have found that, over a period of five months ... naturally-occurring bacteria that exist in the Gulf of Mexico consumed ... gas that spewed into the deep Gulf from the ruptured ... to determine not only how much oil and gas was ...
... to change their behavior if they voluntarily commit to ... to a new study in the Journal of ... you,re trying to encourage more eco-friendly behavior. "Commitment ... specific steps to promote the desired behavior. Consumers who ...
Cached Biology News:Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 2Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 3Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 4Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 5At least 200,000 tons of oil and gas from Deepwater Horizon spill consumed by gulf bacteria 2At least 200,000 tons of oil and gas from Deepwater Horizon spill consumed by gulf bacteria 3Want to encourage eco-friendly behavior? Give consumers a nudge (Don't tell them what to do) 2
... FAST RED Chromogen System consists ... substrate buffer. FAST RED reacts ... phosphatase to produce red staining ... The FAST RED ...
Mouse Cell Line Slides...
Human Cell Line Slides...
... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
Biology Products: